HBM Holdings Limited provided earnings guidance for the six months ended 30 June 2023. For the period, the total revenue of the Group for the six months ended 30 June 2023 is expected to be approximately USD 40.0 million, representing an increase of approximately 44.9% from approximately USD 27.6 million for the six months ended 30 June 2022; and (ii) a profit for the period within the range of USD 2.0 million to USD 4.0 million for the six months ended 30 June 2023, compared to a loss for the period of approximately USD 73.1 million for the six months ended 30 June 2022. Apart from the improved cost control through enhanced business operation efficiency, the anticipated increase in total revenue and turnaround from loss to profit were also mainly attributable to: the out-licensing and collaboration of innovative products from the portfolio of Harbour Therapeutics, such as HBM7008 and HBM9161, which contributed significantly to the revenue for the six months ended 30 June 2023; and the significant increase in revenue of Nona Biosciences, which reflects its rapid momentum of development and expansion.